Research programme: CD40 agonists - Apogenix

Drug Profile

Research programme: CD40 agonists - Apogenix

Alternative Names: APG 1233; APG 1274; HERA-CD40L - Apogenix; scCD40L-RBD-Fc

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Apogenix
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action CD40 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Nov 2016 Pharmacokinetics and Pharmacodynamics data from preclinical and in vitro studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 15 Dec 2015 Research programme: CD40 agonists - Apogenix is available for licensing as of 15 Dec 2015. www.apogenix.com
  • 15 Dec 2015 Preclinical trials in Solid tumours in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top